Printer Friendly

Amneal to unveil generic Isoproterenol Hydrochloride Injection USP in the US.

M2 EQUITYBITES-October 22, 2018-Amneal to unveil generic Isoproterenol Hydrochloride Injection USP in the US

(C)2018 M2 COMMUNICATIONS http://www.m2.com

Amneal Pharmaceuticals Inc (NYSE:AMRX) revealed on Friday the receipt of US FDA approval for the generic version of Isuprel Injection (isoproterenol hydrochloride) USP in 0.2 mg/ml and 1 mg/5 ml(0.2 mg/ml) Single-Dose Vials.

Effective immediately, the company has initiated commercialisation activities for Isuprel Injection (isoproterenol hydrochloride) USP in 0.2 mg/ml and 1 mg/5 ml(0.2 mg/ml) Single-Dose Vials. Isoprenaline, or isoproterenol, is a medication used for the treatment of bradycardia (slow heart rate), heart block and rarely for asthma.

According to IQVIA, US market annual sales for the 12 months ended August 2018 for Isoproterenol Hydrochloride Injection USP in 0.2 mg/ml and 1 mg/5 ml(0.2 mg/ml) Single-Dose Vials is estimated to be approximately USD158m.

Headquartered in Bridgewater, NJ, the pharmaceutical company is focused on developing, manufacturing and distributing generic, brand and biosimilar products.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Oct 22, 2018
Words:184
Previous Article:Recipharm decides to continue manufacturing operations in HA[pilcrow sign]ganas, Sweden.
Next Article:MC3 Cardiopulmonary awarded US FDA clearance for Crescent for Veno-Venous Extracorporeal Membrane Oxygenation for acute respiratory failure.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters